It is a new treatment once morest Covid-19 that might be authorized in France. On January 7, the Haute Autorité de Santé (HAS) gave the green light for early access to Xevudy (sotrovimab molecule), a monoclonal antibody developed by the laboratories GlaxoSmithKline (GSK, UK) and Vir Biotechnology (United States). Authorized for marketing since December 17 by the European Medicines Agency (EMA), Xevudy can be used from the age of 12 in Covid-19 patients weighing more than 40 kg and who are at risk of developing a form serious.
HAS recommends treatment of GSK resistant to Omicron against Covid-19
